Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(1):4-18
The high prevalence of invasive candidiasis (IC) in intensive care units (ICU) is one of the major problems of medical mycology and the modern medicine in general. More than 10% of all infections in ICU are caused by Candida spp. Infections caused by Candida species are associated with the high mortality, including patients in ICUs. The high rates of attributive mortality and the changing epidemiology of IC causative agents requires the precise approaches from clinicians for selecting of adequate antifungal agents first of all for the empiric therapy. For today the antifungal agents for the therapy of IC in ICU are limited to echinocandins and azole antifungals. Taking into account the importance of de-escalation therapy strategy, echinocandins in the majority of cases are the preparations of choice, because of their good tolerability profile and retaining high fungicidal activity against Candida spp. The major approaches for selecting antifungal agents for the empiric therapy of IC in ICU patients are presented in the current article.